Answers are grounded in this paper and cite their sources.
Novartis is the latest drug company to buy up a radiopharmaceutical -focused biotech firm with its planned purchase of Mariana Oncology for $1 billion. Radiopharmaceuticals are not a new area for Novartis, which already sells the lutetium-177-based drugs Lutathera and Pluvicto. Mariana brings with it a roster of ligands with radionuclides that emit α and β particles. The company's lead compound, MC-339, is an actinium-255-containing radioligand therapy to treat small-cell lung cancer.—
No takes yet. Share an insight, caveat, or question.
Laura Howes (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: